News

Two single variants in immune system-related genes may help predict ankylosing spondylitis with active disease response to therapy. The study “The Diagnostic and Prognostic Role of Interleukin 12B and Interleukin 6R Gene Polymorphism in Patients With Ankylosing Spondylitis” was published in the Journal of Clinical Rheumatology. Two pathways…

Antibe Therapeutics has fully enrolled a trial comparing the gastrointestinal safety of investigative compound ATB-346 with naproxen, a nonsteroidal anti-inflammatory drug (NSAID). The Phase 2b trial is running as scheduled, and the company plans to release top-line data within six weeks. Naproxen, sold under the brand names Aleve, Naprosyn, and others, is one of the…

Intravenous infusion of Simponi Aria (golimumab) significantly improves ankylosing spondylitis (AS) symptoms in adults, an ongoing Phase 3 trial shows. The results through week 28 of the GO-ALIVE trial were published in the Journal of Rheumatology in an article titled “Safety and Efficacy of Golimumab Administered…

The European Union has expanded its approval of the rheumatic disease therapy UCB’s Cimzia t0 include women who are pregnant or breastfeeding. UCB’s treatment becomes the first anti-tumor necrosis factor (TNF) therapy to cover these patients. The label change was approved by the European Medicines Agency. TNF is a pro-inflammatory cytokine, or molecule…